Balixafortide: what the breast cancer trials found
Clinical review pending
Balixafortide was studied alongside eribulin for metastatic breast cancer. The controlled trial found no additional benefit.
What is balixafortide?
Balixafortide is an experimental peptide that blocks the CXCR4 receptor. This receptor helps regulate how cells move through the body and interact with their surroundings. The medicine was developed by Polyphor, later Spexis, under the name POL6326. In trials, it was given intravenously alongside the chemotherapy medicine eribulin for HER2-negative metastatic breast cancer. According to the source text, it is not approved and its development has effectively stopped.
How is balixafortide supposed to work?
Balixafortide blocks the CXCR4 receptor 1, interrupting its signaling with the binding partner CXCL12, also called SDF-1α. This pathway influences tumor-cell migration, the tumor environment and immune-cell behavior. Laboratory research suggested that blocking CXCR4 might make tumors more sensitive to chemotherapy. This was the rationale for combining it with eribulin. The mechanism alone does not establish a benefit for patients.
Is balixafortide FDA-approved?
No. At the point described in the source text, balixafortide was not approved. The development program effectively stopped after the pivotal trial.
What do the studies show?
The key controlled trial had a negative result. Two studies tested the combination of balixafortide and eribulin in metastatic breast cancer:
The controlled evidence does not support an additional benefit from balixafortide.
Studies at a glance
| Study | Study design | Finding |
|---|---|---|
| Phase 1 study [1], according to PubMed | Early study without a comparison group in heavily pretreated metastatic breast cancer | Around 30% of evaluable participants had a partial response. This was an encouraging signal from an uncontrolled study. |
| Phase 3 FORTRESS trial [2], company report from 2021 | Randomized comparison with eribulin alone | The primary endpoint was not met. Response rates and clinical benefit were similar to those with eribulin alone; adding balixafortide produced no meaningful improvement. |
References cited in the source text
Sources: the Phase 1 dose-escalation trial (Pernas et al., The Lancet Oncology, 2018, DOI: 10.1016/S1470-2045(18)30147-5 1), indexed on PubMed; and company reporting of the Phase 3 FORTRESS result.
Provenance and editorial review status
Adapted for Nutrient Desk from the source article. The claims and source attributions in the original text still require clinical review. This draft has not been cleared for indexing.